A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

Inclusion Criteria:

1. At the time of signing the informed consent form (ICF): Part 1 only: healthy maleand female participants aged between 18 and 45 years inclusive; Part 2 only: healthywomen aged between 40 and 65 years inclusive who have undergone natural menopause;

2. Body weight >=50 kilogram (kg) (male), >=45 kg (female) with a body mass indexbetween 18.0 and 32.0 kilogram per square meter (kg/m^2) inclusive at screening;

3. Part 1 only: Female participants are eligible to participate if they are notpregnant, not breastfeeding, and highly effective contraception includes placementof an intrauterine device or intrauterine system plus use of a condom;

4. Part 1 only: Male participants must agree to practice true abstinence; be surgicallysterilized; or agree to use a condom plus effective contraception for their femalepartner, if of childbearing potential, from screening and for at least 90 days afterdosing and refrain from donating sperm during this period. These contraceptionrequirements do not apply if the male participant is in an exclusively same sexrelationship;

5. Able to comprehend the nature of the study and any risks associated withparticipation and willing to cooperate and comply with protocol restrictions andrequirements.

Exclusion Criteria:

1. Any known allergy to the components or analogues of the investigational product, orthose with an allergic constitution;

2. A history of currently suffering from any other cardiovascular, gastrointestinal,endocrine, hematological, hepatic, immunological, metabolic, urinary, pulmonary,neurological, dermatological, psychiatric, renal and/or other major diseases deemedclinically significant by the investigator;

3. Known/confirmed history of malignancy;

4. A history of epileptic seizure or increased risk of epileptic seizure, orparticipants with a recent history of head trauma leading to loss of consciousnessor concussion;

5. A history of currently suffering from hypothalamic dysfunction;

6. Significant acute/chronic infections within two weeks prior to dosing;

7. Undergone major surgical procedures within six months prior to screening or plan toundergo any surgery during the trial;

8. Participated in other clinical trials within 1 month prior to dosing;

9. Have lost or donated more than 400 mL of blood within 1 month prior to screening;

10. Have taken any prescription/over-the-counter drugs or dietary supplements within 7days prior to dosing or within 5 halflives of the drug;

11. Clinically significant abnormalities on physical examination or genitourinaryultrasound at the time of screening;

12. Clinically significant abnormalities in vital signs;

13. Prolonged QTcF interval in 12-lead ECG results ;

14. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkalinephosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), bloodcreatinine (CRE), blood urea nitrogen (BUN), or international normalized ratio (INR)higher than the upper limit of normal (ULN) at screening, that are considered asclinically significant abnormalities by the investigator;

15. Part 2 only: abnormal sex hormone levels at screening that are considered clinicallysignificant by the investigator;

16. Clinically significant abnormalities in thyroid function, parathyroid function, andneck ultrasound results at screening;

17. Women with positive pregnancy test result or those who are breastfeeding beforedosing;

18. Positive hepatitis C virus antibody (HCV Ab), positive human immunodeficiency virusantibody (HIV Ab) or positive hepatitis B surface antigen (HbsAg) result atscreening;

19. Unable to refrain from consuming grapefruit, pomelo, grapefruit juice, or pomelojuice from 48 hours prior to check-in until the end of the study;

20. Unable to refrain from consuming any foods or beverages containing caffeine orxanthine from 48 hours prior to check-in until the end of the study;

21. Unable to abstain from smoking/using tobacco products from 48 hours prior tocheck-in until the end of the study;

22. Unable to refrain from consuming alcohol from 48 hours prior to check-in until theend of the study;

23. Any history of narcotic use or drug abuse;

24. Any medical or other condition may affect the clinical trial.